Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
INAB 
In8bio Inc (INAB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: INAB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $58.1
1 Year Target Price $58.1
| 2 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -65.81% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 10.35M USD | Price to earnings Ratio - | 1Y Target Price 58.1 |
Price to earnings Ratio - | 1Y Target Price 58.1 | ||
Volume (30-day avg) 4 | Beta 0.01 | 52 Weeks Range 1.98 - 16.71 | Updated Date 08/29/2025 |
52 Weeks Range 1.98 - 16.71 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -9.08 |
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.06 | Actual -1.24 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -69.05% | Return on Equity (TTM) -165.56% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 151760 | Price to Sales(TTM) - |
Enterprise Value 151760 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.15 | Shares Outstanding 4539720 | Shares Floating 4179036 |
Shares Outstanding 4539720 | Shares Floating 4179036 | ||
Percent Insiders 5.56 | Percent Institutions 19.29 |
Upturn AI SWOT
In8bio Inc
Company Overview
History and Background
In8bio Inc. is a clinical-stage biopharmaceutical company focused on developing gamma-delta T cell therapies for cancer. Founded in 2016, it leverages its DeltEx platform to develop engineered gamma-delta T cell product candidates.
Core Business Areas
- Gamma-Delta T Cell Therapy Development: In8bio's primary focus is on developing allogeneic and autologous gamma-delta T cell therapies for the treatment of solid tumors and hematological malignancies.
Leadership and Structure
The company is led by a management team with expertise in cell therapy and oncology. Its organizational structure includes research, development, and clinical operations departments.
Top Products and Market Share
Key Offerings
- INB-400: An autologous DeltEx DRI T cell therapy for recurrent glioblastoma (GBM). Competitors include other cell therapy companies and standard of care treatments for GBM.
- INB-200: An allogeneic DeltEx DRI T cell therapy for hematological malignancies. Competitors include other cell therapy companies and standard chemotherapy regimens.
Market Dynamics
Industry Overview
The cell therapy market is rapidly growing, driven by advancements in immunotherapy and personalized medicine. There is a high unmet need for effective cancer treatments.
Positioning
In8bio is positioned as an innovator in the gamma-delta T cell therapy space, focusing on novel engineered cell therapies.
Total Addressable Market (TAM)
The global cell therapy market is projected to reach hundreds of billions of dollars, representing a significant TAM. In8bio's success depends on demonstrating the efficacy and safety of its product candidates.
Upturn SWOT Analysis
Strengths
- Proprietary DeltEx platform
- Focus on engineered gamma-delta T cells
- Clinical-stage product candidates
- Experienced management team
Weaknesses
- Limited financial resources
- Clinical trial risks
- Dependence on successful product development
- Competition from established cell therapy companies
Opportunities
- Growing cell therapy market
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- Positive clinical trial results
Threats
- Regulatory hurdles
- Competition from other immunotherapies
- Clinical trial failures
- Intellectual property disputes
Competitors and Market Share
Key Competitors
- CRIS
- TCR2
- NK
- AGEN
Competitive Landscape
In8bio faces competition from companies developing other cell therapies and immunotherapies. Its advantage lies in its proprietary DeltEx platform. A disadvantage is its limited resources compared to larger companies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth requires specific financial data that cannot be provided without live access.
Future Projections: Future projections are dependent on successful clinical trials and market adoption, which are subject to change.
Recent Initiatives: Recent initiatives include advancing clinical trials for INB-400 and INB-200.
Summary
In8bio is a clinical-stage biopharmaceutical company focused on developing innovative gamma-delta T cell therapies, which makes it a high-risk, high-reward investment. While their DeltEx platform is a strength, their limited financial resources represent a vulnerability. Successful clinical trial results are essential for their growth, but regulatory hurdles and competition pose threats. Their position in the growing cell therapy market makes it an attractive consideration for some.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data and market conditions are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About In8bio Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2021-07-30 | Co-Founder, President, CEO & Director Mr. Tai-Wei Ho | ||
Sector Healthcare | Industry Biotechnology | Full time employees 18 | Website https://in8bio.com |
Full time employees 18 | Website https://in8bio.com | ||
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its products include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company also develops INB-619, a gamma-delta TCE targeting CD19 for both oncology and autoimmune diseases; INB-300, a nsCAR-enabled DeltEx product candidates targeting difficult liquid tumors and extracranial solid tumors; and INB-500, an induced pluripotent stem cell derived gamma-delta T cells that are in preclinical phase for treatment of cancer. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is based in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.